Although only exon 17 mutations in KIT have been established as a poor prognostic factor in RUNX1::RUNX1T1-AML (30), other KIT activating mutations may also serve as potential molecular targets for AML treatment, particularly in relapsed cases (31). This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.